A simple and rapid method for the quantitation of secreted hepatitis B virions in cell culture models

We report the development of an assay using a commercially available HBsAg-ELISA plate for immunocapture followed by real-time PCR for quantification of hepatitis B virions in cell cultures. This assay is rapid, highly sensitive (50 copies/reaction) and highly specific for virion-associated DNA. In addition, the assay requires only 20 μL of supernatant, allowing scaling down of transfections.
Source: Indian Journal of Medical Microbiology - Category: Microbiology Authors: Source Type: research

Related Links:

AbstractPurpose of ReviewTo review the evidence for stopping antiviral therapy with nucleos(t)ide analogues (NA) in patients with chronic hepatitis B.Recent FindingsHBsAg loss is usually stable even without anti-HBs seroconversion after stopping NA therapy. About 50% of HBeAg-positive patients who have achieved anti-HBe seroconversion and have stopped NA therapy remain in virological remission. Consolidation therapy increases the response rate. In HBeAg-negative hepatitis, stable virological remission is documented in 30% after NA discontinuation. Interestingly, some studies document unexpectedly high long-term HBsAg loss ...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
First of all, we greatly appreciate the letter from Yu et al.,1 which addressed several concerns regarding our study2 where we concluded that the risk of hepatocellular carcinoma (HCC) was not statistically different between patients treated with entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF) for chronic hepatitis B virus (HBV) infection. Actually, the controversy concerning which antiviral agent is better in improving prognosis among patients with chronic HBV infection remains, however, the level of evidence favoring the use of any specific antiviral agent has been weak.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
ConclusionsDespite being on ART, a significant proportion of HIV/HBV-coinfected individuals present HBV viremia. Characterization of factors that are associated with this finding may help professionals provide better management to these patients.
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
We present a case of female patient who was referred to the consultation because she was about to start chemotherapy with an anti-CD20 agent and had a positive anti-HBc and anti-HBs. During routine workup an occult hepatitis B virus infection was diagnosed. Upon further study mutations in the PreCore and Basal Core Promoter regions were identified, as well as, a double genotype D/C. Therapy with tenofovir was initiated before the patient was started on chemotherapy. This case highlights the importance of comprehensive studying of patients who present with apparently resolved chronic hepatitis B virus infection, especially ...
Source: IDCases - Category: Infectious Diseases Source Type: research
Publication date: Available online 9 November 2019Source: Biosensors and BioelectronicsAuthor(s): Masumi Iijima, Tsutomu Nakayama, Shun'ichi KurodaAbstractThe orientation and density of biosensing molecules on sensor chip should be precisely controlled to improve sensitivity and ligand-binding capacity. We previously developed a ∼30-nm bio-nanocapsule (ZZ-BNC), consisting of the hepatitis B virus envelope L protein fused with the tandem form of protein A-derived IgG Fc-binding Z domain (ZZ-L protein). This is used as a robust nanoparticle scaffold to enhance the sensitivity and ligand-binding capacity of IgGs and Fc-fu...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Identification and knowledge of settings with high prevalence of hepatitis C virus (HCV) infection is important when aiming for elimination of HCV. The primary aim of this study was to estimate the prevalence ...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Research article Source Type: research
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: Entecavir Tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Hepatitis b Interventions:   Drug: TDF tablet;   Drug: Entecavir Tablet;   Drug: QL-007 Sponsor:   Qilu Pharmaceutical Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hepatitis | Hepatitis B | Microbiology